RaymondChungMD

Gastroenterology • Boston, MA

Hepatology & Liver Transplantation

Director of Hepatology and Liver Center, Vice Chief of Gastroenterology, Mass General Hospital Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Chung is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chung's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-6006

Fax+1 617-724-6832

Education & Training

MedStar Health (Baltimore)Residency, Internal Medicine, 1989
Yale School of MedicineClass of 1986
Massachusetts General HospitalFellowship, Gastroenterology

Certifications & Licensure

MA State Medical License 1989 - 2025
MD State Medical License 1983 - 2018
VA State Medical License 2000 - 2018
AZ State Medical License 2008 - 2015
TX State Medical License 2001 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Clinical Trials

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant Start of enrollment: 2017 Nov 09
Terminated
Phase 4
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk Start of enrollment: 2023 May 10
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator

Publications & Presentations

PubMed

Ironing out MAFLD: Therapeutic targeting of liver ferroptosis.
Tuo Shao, Raymond T Chung
Cell Metabolism. 2024-10-01
Association of HRS-AKI with Mortality in Patients with Cirrhosis Requiring Renal Replacement Therapy: Results from the HRS-HARMONY Consortium.
Augusto Cama-Olivares, Tianqi Ouyang, Tomonori Takeuchi, Shelsea A St Hillien, Jevon E Robinson
Kidney360. 2024-09-30
1 citations
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH.
Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale
Journal of Hepatology. 2024-09-25

Press Mentions

State Prisons Won’t Treat Curable Hepatitis C for 144,000 InmatesJuly 13th, 2018
PBC Drug Promising in New SettingOctober 24th, 2017
Surprising Complications of Hepatitis CMay 31st, 2016
Join now to see all